AR069437A1 - Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol - Google Patents
Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazolInfo
- Publication number
- AR069437A1 AR069437A1 ARP080105163A ARP080105163A AR069437A1 AR 069437 A1 AR069437 A1 AR 069437A1 AR P080105163 A ARP080105163 A AR P080105163A AR P080105163 A ARP080105163 A AR P080105163A AR 069437 A1 AR069437 A1 AR 069437A1
- Authority
- AR
- Argentina
- Prior art keywords
- imidazol
- compounds
- bisphosphonates
- rent
- carbon atoms
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 150000004663 bisphosphonates Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 abstract 1
- 208000007932 Progeria Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen ácidos [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonicos sustituidos por alquilo C2-5, así como métodos o procesos para su fabricacion, y composiciones farmacéuticas que los abarcan, y/o los compuestos para utilizarse en el tratamiento de enfermedades. Los compuestos son utiles de inhibir la resorcion osea excesiva o inapropiada, y para al tratamiento de otras enfermedades que sean causadas por una prenilacion excesiva de las proteínas objetivo, tales como síndrome de progeria de Hutchinson-Gilford. Los compuestos son de la formula 1, en donde uno de R1 y R2 es hidrogeno, y el otro es alquilo C2-5 que está ramificado o no ramificado, y que pueden estar en forma libre o en la forma de un éster, y/o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122016 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069437A1 true AR069437A1 (es) | 2010-01-20 |
Family
ID=39154111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105163A AR069437A1 (es) | 2007-11-30 | 2008-11-27 | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7977323B2 (es) |
| EP (1) | EP2225252B1 (es) |
| JP (1) | JP5244917B2 (es) |
| KR (1) | KR20100092035A (es) |
| CN (1) | CN101835787A (es) |
| AR (1) | AR069437A1 (es) |
| AU (1) | AU2008328797B2 (es) |
| BR (1) | BRPI0819902A2 (es) |
| CA (1) | CA2701516A1 (es) |
| CL (1) | CL2008003545A1 (es) |
| CO (1) | CO6280421A2 (es) |
| CR (1) | CR11362A (es) |
| EA (1) | EA201000860A1 (es) |
| EC (1) | ECSP10010321A (es) |
| ES (1) | ES2386851T3 (es) |
| IL (1) | IL204657A0 (es) |
| MA (1) | MA31895B1 (es) |
| MX (1) | MX2010005786A (es) |
| NZ (1) | NZ584219A (es) |
| PE (1) | PE20091038A1 (es) |
| TN (1) | TN2010000138A1 (es) |
| TW (1) | TW200932248A (es) |
| WO (1) | WO2009068567A1 (es) |
| ZA (1) | ZA201001992B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2273980A2 (en) * | 2008-04-04 | 2011-01-19 | Novartis AG | Pharmaceutical composition with bisphosphonate |
| EP2459176B1 (en) | 2009-07-31 | 2017-09-27 | Grünenthal GmbH | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| CN102659840B (zh) * | 2012-05-10 | 2013-08-14 | 苏州普瑞诺药物技术有限公司 | 咪唑双膦酸类化合物及其可药用盐及药物用途 |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| US20210008084A1 (en) | 2017-10-16 | 2021-01-14 | Tsinghua University | Mevalonate pathway inhibitor and pharmaceutical composition thereof |
| CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84497A (en) | 1986-11-21 | 1994-10-21 | Ciba Geigy Ag | History 2-) Imidazol-1-yl (ethane-1,1-diphosphonic acid, their preparation and pharmaceutical preparations containing them |
| HU215124B (hu) * | 1991-02-26 | 1998-09-28 | Norwich Eaton Pharmaceuticals, Inc. | Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására |
| GB9324143D0 (en) | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
| GB0029018D0 (en) * | 2000-11-28 | 2001-01-10 | Strakan Group Plc | Dermatological formulations |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| WO2006039721A2 (en) | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| WO2008040763A1 (en) | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
| EP2139888A2 (en) | 2007-03-28 | 2010-01-06 | Array Biopharma, Inc. | Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors |
-
2008
- 2008-11-26 WO PCT/EP2008/066245 patent/WO2009068567A1/en active Application Filing
- 2008-11-26 KR KR1020107014395A patent/KR20100092035A/ko not_active Application Discontinuation
- 2008-11-26 ES ES08854485T patent/ES2386851T3/es active Active
- 2008-11-26 US US12/323,696 patent/US7977323B2/en not_active Expired - Fee Related
- 2008-11-26 EA EA201000860A patent/EA201000860A1/ru unknown
- 2008-11-26 BR BRPI0819902-7A patent/BRPI0819902A2/pt not_active IP Right Cessation
- 2008-11-26 JP JP2010535369A patent/JP5244917B2/ja active Active
- 2008-11-26 NZ NZ584219A patent/NZ584219A/en not_active IP Right Cessation
- 2008-11-26 CA CA2701516A patent/CA2701516A1/en not_active Abandoned
- 2008-11-26 AU AU2008328797A patent/AU2008328797B2/en not_active Ceased
- 2008-11-26 EP EP08854485A patent/EP2225252B1/en active Active
- 2008-11-26 MX MX2010005786A patent/MX2010005786A/es active IP Right Grant
- 2008-11-26 CN CN200880112351A patent/CN101835787A/zh active Pending
- 2008-11-27 PE PE2008001990A patent/PE20091038A1/es not_active Application Discontinuation
- 2008-11-27 AR ARP080105163A patent/AR069437A1/es active IP Right Grant
- 2008-11-28 CL CL2008003545A patent/CL2008003545A1/es unknown
- 2008-11-28 TW TW097146484A patent/TW200932248A/zh unknown
-
2010
- 2010-03-19 ZA ZA2010/01992A patent/ZA201001992B/en unknown
- 2010-03-22 IL IL204657A patent/IL204657A0/en unknown
- 2010-03-26 TN TNP2010000138A patent/TN2010000138A1/fr unknown
- 2010-04-09 CR CR11362A patent/CR11362A/es unknown
- 2010-05-26 CO CO10063351A patent/CO6280421A2/es not_active Application Discontinuation
- 2010-05-31 MA MA32880A patent/MA31895B1/fr unknown
- 2010-06-30 EC EC2010010321A patent/ECSP10010321A/es unknown
-
2011
- 2011-05-26 US US13/116,671 patent/US20110224173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20091038A1 (es) | 2009-08-19 |
| NZ584219A (en) | 2012-03-30 |
| JP5244917B2 (ja) | 2013-07-24 |
| TW200932248A (en) | 2009-08-01 |
| ECSP10010321A (es) | 2010-08-31 |
| CO6280421A2 (es) | 2011-05-20 |
| EP2225252A1 (en) | 2010-09-08 |
| WO2009068567A1 (en) | 2009-06-04 |
| TN2010000138A1 (en) | 2011-09-26 |
| EP2225252B1 (en) | 2012-06-27 |
| MA31895B1 (fr) | 2010-12-01 |
| KR20100092035A (ko) | 2010-08-19 |
| US20090143337A1 (en) | 2009-06-04 |
| CL2008003545A1 (es) | 2009-06-05 |
| CA2701516A1 (en) | 2009-06-04 |
| AU2008328797B2 (en) | 2011-11-03 |
| MX2010005786A (es) | 2010-06-09 |
| US20110224173A1 (en) | 2011-09-15 |
| ZA201001992B (en) | 2010-12-29 |
| US7977323B2 (en) | 2011-07-12 |
| BRPI0819902A2 (pt) | 2015-05-19 |
| CR11362A (es) | 2010-06-14 |
| IL204657A0 (en) | 2010-11-30 |
| ES2386851T3 (es) | 2012-09-03 |
| AU2008328797A1 (en) | 2009-06-04 |
| CN101835787A (zh) | 2010-09-15 |
| JP2011504908A (ja) | 2011-02-17 |
| EA201000860A1 (ru) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069437A1 (es) | Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| BR112012030923B8 (pt) | Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo | |
| DOP2009000164A (es) | Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina | |
| AR091857A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| NI200900107A (es) | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. | |
| NI201100081A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes. | |
| UY32990A (es) | Derivados de ácido carboxílico cíclico sustituidos con acilamino y su uso como productos farmacéuticos | |
| SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
| NI200800024A (es) | Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa | |
| BR112013023847A2 (pt) | composições farmacêuticas compreendendo ésteres de sorbitano | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| BRPI0512690A (pt) | análogos de fosfonato de compostos inibidores de hiv | |
| SV2009003312A (es) | Derivados de isoquinolina e isoquinolinona sustituidos | |
| MX2016016830A (es) | Complejos de aminoacidos minerales de agentes activos. | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| CR20140412A (es) | Inhibidores de la metalproteinasa matriz | |
| BRPI0607093A2 (pt) | polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende | |
| PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
| EA201270410A1 (ru) | Производное инденона и содержащая его фармацевтическая композиция | |
| BRPI0809542A8 (pt) | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos | |
| BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
| AR046228A1 (es) | Derivados de indol como activadores ppar, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de medicamentos. | |
| CU20100108A7 (es) | Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol | |
| PE20081360A1 (es) | Compuestos analogos de lipoxina a4 para el tratamiento y prevencion de la fibrosis intestinal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |